Skip to content
PeptideFactSheets
Plain-English comparison

Peptides for weight management: approved versus experimental

A status-first look at approved medicines and experimental peptides discussed for body weight.

By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.

The quick overview

The phrase “peptides for weight loss” mixes together approved prescription medicines, research drugs, products approved for a different narrow purpose, and unapproved substances with little human evidence.

Semaglutide, tirzepatide, and liraglutide have products approved for chronic weight management in defined populations. Retatrutide is still investigational despite company-reported Phase 3 top-line results. Tesamorelin has a narrow HIV-lipodystrophy indication and is not a general weight-loss medicine.

Side-by-side comparison

Semaglutide
FDA approved for specific usesStrong human evidence for approved uses

Studied for

Type 2 diabetes · Chronic weight management · Cardiovascular outcomes

Tirzepatide
FDA approved for specific usesStrong human evidence for approved uses

Studied for

Type 2 diabetes · Chronic weight management · Obstructive sleep apnea in adults with obesity

Liraglutide
FDA approved for specific usesStrong human evidence for approved uses

Studied for

Type 2 diabetes · Chronic weight management · Cardiovascular outcomes

Retatrutide
In clinical trialsModerate human evidence

Studied for

Obesity and overweight · Type 2 diabetes · Cardiovascular and kidney outcomes

Tesamorelin
FDA approved for specific usesStrong human evidence for approved uses

Studied for

HIV-associated lipodystrophy · Visceral abdominal fat · Metabolic measures

Approved versus investigational

An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.

What researchers are studying

  • Chronic weight management
  • Metabolic health and type 2 diabetes
  • Cardiovascular outcomes
  • Specific fat-distribution conditions

Risks and reasons for caution

  • Eligibility, contraindications, side effects, and required follow-up differ by medicine and person.
  • An approval for diabetes, sleep apnea, or HIV lipodystrophy is not blanket approval for every weight-related goal.
  • Unapproved copies and research products do not undergo the same FDA premarket review.

What remains uncertain

  • Long-term outcomes for related medicines and additional indications
  • How best to maintain outcomes after treatment changes
  • Whether investigational candidates will earn approval

Questions to ask a healthcare professional

1. Is this exact product FDA approved for this exact use?

2. What outcome matters besides the number on a scale?

3. What risks or other medicines need review?

4. What is the plan for long-term clinical follow-up?

Plain-English takeaway

Status is the first sorting step: approved product for a specific use, investigational drug in a registered trial, or unapproved substance. Those categories should never blur together.

CompareGLP-1 peptides compared in plain EnglishHow semaglutide, tirzepatide, liraglutide, and investigational retatrutide differ in targets, evidence, and approval status.CompareNext-generation metabolic peptides: beyond GLP-1 aloneHow amylin analogs and glucagon-containing co-agonists differ in targets, trial maturity, liver research, weight evidence, and FDA status.CompareGrowth hormone pathway peptides: what readers should understandHow tesamorelin, sermorelin, CJC-1295, and ipamorelin differ in mechanism, status, and evidence.

References

  1. 1
    fdaFDA prescribing information: Wegovy

    Semaglutide label for chronic weight management and product-specific limitations.

  2. 2
    fdaFDA prescribing information: Zepbound

    Tirzepatide label for chronic weight management and obstructive sleep apnea in adults with obesity.

  3. 3
    fdaFDA prescribing information: Saxenda

    Liraglutide label for chronic weight management in defined adult and pediatric populations.

  4. 4
    fdaFDA prescribing information: Egrifta SV

    Tesamorelin label showing the narrow HIV-lipodystrophy indication and weight-loss limitation.

  5. 5
    clinical trialsClinicalTrials.gov: TRIUMPH-1

    Completed Phase 3 obesity trial record for the investigational retatrutide program.

  6. 6
    company releaseLilly: TRIUMPH-1 top-line results

    Company-provided Phase 3 top-line obesity results; not a peer-reviewed publication or FDA approval.